All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Multiple Myeloma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2019-11-04T16:51:47.000Z

FDA grants Regenerative Medicine Advanced Therapy (RMAT) designation for CAR-T cell therapy, CT053

Nov 4, 2019
Share:

Bookmark this article

On the 28th of October 2019, the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to the investigational chimeric antigen receptor (CAR) T cell therapy, CT053, for the treatment of patients with relapsed/refractory (R/R) multiple myeloma (MM).1

CT053 is a fully human, autologous CAR T-cell therapy against B Cell Maturation Antigen (BCMA), a protein commonly overexpressed in MM, involved in the regulation of B cell proliferation and survival, as well as plasma cell maturation and differentiation. The approval is based on clinical data of an ongoing, three-site Phase I/II trial (NCT03975907) in 84 heavily pre-treated patients with R/R MM. The updated clinical data on efficacy and safety will be presented during the 61st American Society of Hematology meeting in December this year.

The drug has previously received Orphan Drug designation from the FDA (read here) and priority medicines (PRIME) eligibility from the European Medicines Agency (EMA).

  1. CARsgen Therapeutics. CARsgen Announces Investigational CAR-T Therapy CT053 Granted RMAT Designation by the U.S. FDA for R/R Multiple Myeloma. Press release 28th October 2019. http://www.carsgen.com/media/news?id=BskN4xpfq8 [Accessed November 4, 2019]

Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox